CANADA: Tilray, a global leader in medical cannabis research and production, today announced that Tilray cannabinoid products have arrived and are cleared for distribution in European Union member state Cyprus after the company received necessary approvals in Canada and Cyprus to export cannabinoid formulations for patients in Cyprus.
“We are proud to be able to offer patients access to high-quality, pharmaceutical-grade medical cannabis products in Cyprus,” said Brendan Kennedy, Tilray President.
Tilray is working with the country’s Ministry of Health to import and distribute Tilray Drops, a medical cannabis extract product, at pharmacies and healthcare facilities throughout the country to patients with advanced cases of cancer who have authorization to access medical cannabis products.
Tilray currently supplies pharmaceutical-grade medical cannabis products – including dried whole flower and extract formulations – to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers around the world for commercial, compassionate access and research purposes.
Tilray became the first medical cannabis producer in North America to be Good Manufacturing Practices (GMP) certified in December 2016. As an internationally recognized standard, GMP is designed to ensure that medicines are consistently produced and controlled with the highest levels of quality and purity.
“GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production processes, and it provides regulators and health care providers in countries new to medical cannabis with certainty that Tilray products are the safe and smart choice,” said Dr. Joshua Eades, Tilray’s Chief Science Officer.
GMP certification is enabling Tilray to expand international distribution of its products. In 2016, Tilray made history by becoming the first company to legally export medical cannabis products from North America to the European Union and Australia. In 2017, Tilray is focused on expanding global distribution of its products to additional countries on continents worldwide.
GMP certification also allows Tilray to continue breaking new ground in clinical research, advancing the science, safety and efficacy of medical cannabis for patients with a diverse range of conditions. Tilray currently supplies pharmaceutical-grade medical cannabis products for three different clinical trials in partnership with leading hospitals and universities:
- The first trial is being conducted in partnership with the University of British Columbia to examine the safety and tolerability of medical cannabis for Canadian military veterans and other patients suffering from PTSD.
- The second trial is being conducted in partnership with the University of Sydney, Chris O’Brien Lifehouse and the New South Wales government to study the safety, tolerability and efficacy of cannabinoids for chemotherapy-induced nausea and vomiting.
- The third trial is examining safety and tolerability of cannabinoids in children with Dravet Syndrome (a severe form of treatment-resistant epilepsy) at Toronto’s Hospital for Sick Children.
Tilray plans to announce additional research partnerships in the coming year.